TABLE 3.
Diagnostic performance of all methods for predicting liver cirrhosis in the validation cohort.
| Group One (none vs. steatosis) | Group Two (none/mild vs. moderate/severe steatosis) | |||
|---|---|---|---|---|
| Methods | AUROC (95%CI) | Cutoff value | AUROC (95%CI) | Cutoff value |
| Integrated model | 0.734 (0.638-0.816) | 0.20 | 0.930 (0.863-0.971) | -0.32 |
| Radiomics model | 0.705 (0.607-0.790) | 0.48 | 0.807 (0.718-0.878) | -0.22 |
| Clinical model | 0.657 (0.557-0.748) | -0.10 | 0.904 (0.830-0.953) | -2.88 |
| FLI | 0.595 (0.494-0.691) | NA | NA | NA |
| CTL/S | 0.600 (0.499-0.695) | 7.67 | 0.814 (0.726-0.884) | 7.67 |
| Triglycerides | 0.681 (0.582-0.769) | 0.96 | 0.802 (0.712-0.874) | 1.53 |
| Comparison of AUROC (Delong test) | ||||
| Integrated model vs. Clinical model | P = .005 | P =.397 | ||
| Integrated model vs. Radiomics model | P = .035 | P =.016 | ||
| Integrated model vs. FLI | P = .026 | NA | ||
AUROC, area under the receiver operating characteristic; FLI, fatty liver index.